

Dec 21, 2013
NCT01863550: Phase 3 - Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in NDMM
ENDURANCE TRIAL - ECOG-E1A11 (the ENDURANCE trial; E1A11) KRd VRd Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in...
188


Dec 20, 2013
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...
123


Dec 19, 2013
NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)
MMY2002 (SIRIUS) Study An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior...
290


Dec 19, 2013
NCT01998971: Phase 1 - JNJ-54767414 (HuMax CD38) (Anti-CD38 Mono. Ab. ) in Myeloma EQUULEUS; MMY1001
Phase 1 b EQUULEUS study EQUULEUS; MMY1001 Study A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With...
763


Dec 15, 2013
NCT01816971: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After ASCT NDMM
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple...
142


Dec 14, 2013
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2
CHAMPION 2 NCT01980589: Phase 1: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly...
69


Dec 13, 2013
FDA Approved for RRMM: Pomalidomide (Pomalyst)
SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 8, 2013-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration...
112


Dec 13, 2013
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)
RVD Lite NDMM NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite) This research study is a...
268


Dec 12, 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) The purpose of this study is to assess the...
86


Dec 11, 2013
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
wCCyd EMN European Myeloma Network NCT01857115: Phase 1/2: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly...
112


Dec 11, 2013
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic...
68


Dec 7, 2013
NCT01946477: Phase 2 -Pomalidomide Combination With Low-dose Dex +/- Dara in RRMM Myeloma POM MM 014
POM MM 014 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and...
65


Dec 6, 2013
NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of Carfilzomib (CFZ) in...
204


Dec 6, 2013
NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose
NCT01775553: Phase 2: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib The...
156


Dec 6, 2013
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
TOURMALINE-MM2 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With...
137


Dec 5, 2013
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
Phase III study PETHEMA (GEM2012MENOS65) GEM12 MENOS65 PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa...
318


Dec 5, 2013
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
235

